ANTIVIRAL DRUGS ADVISORY COMMITTEE MEETING
January 10, 2001
NDA 21-227, Cancidas™ (caspofungin acetate) Injection, Merck Research Laboratories, proposed for treatment of invasive aspergillosis in patients refractory to, or intolerant of, other therapies.
Treatment of Aspergilosis, John R Perfect MD, Duke University Medical Center ppt htm
Safety and Efficacy of CANCIDAS (caspofungin acetate) in Invasive Aspergillosis, Eileen Navarro, MD, FDA ppt html
Merck Research Laboratories
The statements contained in this document are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Introduction, Tamra Goodrow, PhD, Merck Research Laboratories
Caspofungin Development Program, Carole Sable, MD, Merck Research Laboratories
Concluding Remarks, Jeffrey Chodakewitz, MD, Merck Research Laboratories
Merck Backup Slides